Comparative studies of inosine pranobex and acyclovir

Area of Science:

• Virology
• Dermatology
• Pharmacology

Background:

• Genital herpes is a common sexually transmitted infection caused by the herpes simplex virus.
• Current treatments aim to reduce symptom severity and duration, but do not eliminate the virus.
• Acyclovir and inosine pranobex are antiviral agents with differing mechanisms of action.

Purpose of the Study:

• To compare the efficacy of acyclovir and inosine pranobex in treating first-attack genital herpes.
• To evaluate the impact of these drugs on viral shedding and symptom duration.
• To assess the effect of acyclovir and inosine pranobex on the frequency of genital herpes recurrences.

Main Methods:

• A randomized trial involving 77 patients with first-episode genital herpes.
• Patients received acyclovir (400 mg QID), inosine pranobex (1 g QID), or combination therapy for seven days.
• Outcomes measured included healing time, duration of viral shedding, symptom duration, and recurrence rates.

Main Results:

• Acyclovir treatment resulted in significantly shorter healing times, viral shedding duration, and symptom duration compared to inosine pranobex.
• Neither acyclovir nor inosine pranobex affected the time to first recurrence or the frequency of subsequent recurrences.
• Preliminary data suggest suppressive acyclovir is more effective than inosine pranobex for managing frequently recurring genital herpes.

Conclusions:

• Acyclovir is more effective than inosine pranobex for acute treatment of first-episode genital herpes.
• Neither drug influences the natural course of genital herpes recurrences.
• Acyclovir shows promise for suppressive therapy in patients with frequent genital herpes outbreaks.